Valerio Brisigotti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Valerio Brisigotti has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Elisa Molinelli
Dermatological Unit, Department of Clinical and Molecular Sciences Polytechnic Marche University Ancona Italy
16 shared publications - Anna Campanati
Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
13 shared publications - Annamaria Offidani
Department of Clinical and Molecular Sciences, Dermatology Clinic, Polytechnic Marche University, via Conca 71, 60126 Ancona, Italy
13 shared publications - Federico Diotallevi
Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University
8 shared publications Annamaria Offidani
Clinica Dermatologica Azienda Ospedaliero‐Universitaria Ospedali Riuniti di Ancona Ancona Italy
7 shared publications- Giulia Radi
Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy
7 shared publications
Latest Publications
- Open Access
- 4 October 2023
- Published by Wiley in JEADV Clinical Practice
- Vol. 3 (1) , 76-85
Head–neck melanoma: Clinical, histopathological and prognostic features of an Italian multicentric study
Background: Primitive location of melanoma could be a relevant prognostic factor. As regards the scalp, some studies indicate a particularly aggressive biological behaviour for this anatomical localisation.Objectives: In this multicentric study, data regarding head–neck melanoma (HNM) have been revised.Methods: The design of the study included two main phases. In this retrospective study, data regarding HNM have been collected and analysed.Results: In summary, our data suggest that the posterior neck is the area most affected by thicker melanomas. Cheeks and neck melanoma are associated with reduced disease‐free years of life and overall survival compared with all other sites of HNM.Conclusions: This study provides useful information in defining the clinical features of HNM, thus improving diagnosis and treatment strategies.
- 4 October 2023
- Published by Wiley in JEADV Clinical Practice
- Vol. 3 (1) , 76-85
Open AccessHead–neck melanoma: Clinical, histopathological and prognostic features of an Italian multicentric study
Background: Primitive location of melanoma could be a relevant prognostic factor. As regards the scalp, some studies indicate a particularly aggressive biological behaviour for this anatomical localisation.Objectives: In this multicentric study, data regarding head–neck melanoma (HNM) have been revised.Methods: The design of the study included two main phases. In this retrospective study, data regarding HNM have been collected and analysed.Results: In summary, our data suggest that the posterior neck is the area most affected by thicker melanomas. Cheeks and neck melanoma are associated with reduced disease‐free years of life and overall survival compared with all other sites of HNM.Conclusions: This study provides useful information in defining the clinical features of HNM, thus improving diagnosis and treatment strategies.
- 31 January 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (6) , E744-E746
Oral oxybutynin chloride therapy in the management of hidradenitis suppurativa: A prospective study
- 31 January 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (6) , E744-E746
Oral oxybutynin chloride therapy in the management of hidradenitis suppurativa: A prospective study
- 5 November 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (3) , E392-E394
Acitretin plus macrolides and acitretin monotherapy in the management of hidradenitis suppurativa
- 5 November 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (3) , E392-E394
Acitretin plus macrolides and acitretin monotherapy in the management of hidradenitis suppurativa
- Open Access
- 18 March 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (6) , e15439
Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild‐to‐moderate hidradenitis suppurativa: A retrospective study
Topical and systemic antibiotic therapy remains the first‐line treatment for mild‐to‐moderate hidradenitis suppurativa (HS). However, literature data on antibiotic resistance in HS are growing. A total of 134 patients with mild‐to‐moderate HS were retrospectively evaluated. Seventy‐three patients (group A) received topical clindamycin 1% and 61 patients (group B) received topical resorcinol 15%. We evaluated the efficacy and tolerability of topical 15% resorcinol versus topical 1% clindamycin in mild‐to‐moderate HS, comparing the clinical response at 12 weeks of treatment. Patients treated with resorcinol 15% showed a significant improvement in Hidradenitis Suppurativa Clinical Response, International Hidradenitis Suppurativa Severity Score System, and Pain Visual Analogue Scale score from baseline compared to patients treated with clindamycin 1%. Topical resorcinol 15% could be a valid alternative to clindamycin in the management of acute and long‐standing HS, limiting antibiotic use and antimicrobial resistance.
- 18 March 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (6) , e15439
Open AccessEfficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild‐to‐moderate hidradenitis suppurativa: A retrospective study
Topical and systemic antibiotic therapy remains the first‐line treatment for mild‐to‐moderate hidradenitis suppurativa (HS). However, literature data on antibiotic resistance in HS are growing. A total of 134 patients with mild‐to‐moderate HS were retrospectively evaluated. Seventy‐three patients (group A) received topical clindamycin 1% and 61 patients (group B) received topical resorcinol 15%. We evaluated the efficacy and tolerability of topical 15% resorcinol versus topical 1% clindamycin in mild‐to‐moderate HS, comparing the clinical response at 12 weeks of treatment. Patients treated with resorcinol 15% showed a significant improvement in Hidradenitis Suppurativa Clinical Response, International Hidradenitis Suppurativa Severity Score System, and Pain Visual Analogue Scale score from baseline compared to patients treated with clindamycin 1%. Topical resorcinol 15% could be a valid alternative to clindamycin in the management of acute and long‐standing HS, limiting antibiotic use and antimicrobial resistance.
- Open Access
Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers
Skin cancers (SC) collectively represent the most common type of malignancy in white populations. SC includes two main forms: malignant melanoma and non-melanoma skin cancer (NMSC). NMSC includes different subtypes, namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Merkel cell carcinoma (MCC), and keratoacanthoma (KA), together with the two pre-neoplastic conditions Bowen disease (BD) and actinic keratosis (AK). Both malignant melanoma and NMSC are showing an increasing incidence rate worldwide, thus representing an important challenge for health care systems, also because, with some exceptions, SC are generally characterized by an aggressive behavior and are often diagnosed late. Thus, identifying new biomarkers suitable for diagnosis, as well as for prognosis and targeted therapy is mandatory. Nicotinamide N-methyltransferase (NNMT) is an enzyme that is emerging as a crucial player in the progression of several malignancies, while its substrate, nicotinamide, is known to exert chemopreventive effects. Since there is increasing evidence regarding the involvement of this enzyme in the malignant behavior of SC, the current review aims to summarize the state of the art as concerns NNMT role in SC and to support future studies focused on exploring the diagnostic and prognostic potential of NNMT in skin malignancies and its suitability for targeted therapy.
Open AccessBeyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers
Skin cancers (SC) collectively represent the most common type of malignancy in white populations. SC includes two main forms: malignant melanoma and non-melanoma skin cancer (NMSC). NMSC includes different subtypes, namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Merkel cell carcinoma (MCC), and keratoacanthoma (KA), together with the two pre-neoplastic conditions Bowen disease (BD) and actinic keratosis (AK). Both malignant melanoma and NMSC are showing an increasing incidence rate worldwide, thus representing an important challenge for health care systems, also because, with some exceptions, SC are generally characterized by an aggressive behavior and are often diagnosed late. Thus, identifying new biomarkers suitable for diagnosis, as well as for prognosis and targeted therapy is mandatory. Nicotinamide N-methyltransferase (NNMT) is an enzyme that is emerging as a crucial player in the progression of several malignancies, while its substrate, nicotinamide, is known to exert chemopreventive effects. Since there is increasing evidence regarding the involvement of this enzyme in the malignant behavior of SC, the current review aims to summarize the state of the art as concerns NNMT role in SC and to support future studies focused on exploring the diagnostic and prognostic potential of NNMT in skin malignancies and its suitability for targeted therapy.
- 24 July 2021
- Published by Springer Nature in Human Cell
- Vol. 34 (6) , 1929-1931
Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma
- 24 July 2021
- Published by Springer Nature in Human Cell
- Vol. 34 (6) , 1929-1931
Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma
- Open Access
- 1 February 2021
- Published by MDPI AG in Dermatopathology
- Vol. 8 (1) , 29-32
Primary Dermal Melanoma: A Rare Clinicopathological Variant Mimicking Metastatic Melanoma
Primary dermal melanoma (PDM) is a rare distinct variant of cutaneous melanoma, predominantly occurring on the extremities of young or middle-aged adults. In comparison to conventional melanoma, PDM is characterized by unexpectedly prolonged survival and long-term survival. Thus, correct identification of this variant is crucial to avoid potential misdiagnosis and establish correct treatment and follow-up. In addition, no consensus and specific guidelines exist on the management of this peculiar subtype of cutaneous melanoma.
- 1 February 2021
- Published by MDPI AG in Dermatopathology
- Vol. 8 (1) , 29-32
Open AccessPrimary Dermal Melanoma: A Rare Clinicopathological Variant Mimicking Metastatic Melanoma
Primary dermal melanoma (PDM) is a rare distinct variant of cutaneous melanoma, predominantly occurring on the extremities of young or middle-aged adults. In comparison to conventional melanoma, PDM is characterized by unexpectedly prolonged survival and long-term survival. Thus, correct identification of this variant is crucial to avoid potential misdiagnosis and establish correct treatment and follow-up. In addition, no consensus and specific guidelines exist on the management of this peculiar subtype of cutaneous melanoma.
- 31 December 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (1) , 46-58
Novel Therapeutic Approaches and Targets for the Treatment of Neutrophilic Dermatoses, Management of Patients with Neutrophilic Dermatoses and Future Directions in the Era of Biologic Treatment
: Neutrophilic dermatoses are a heterogeneous group of inflammatory skin disorders characterized by the presence of a sterile, predominantly neutrophilic infiltrate on histopathology. Universally accepted and validated guidelines for the management of neutrophilic dermatoses do not exist, also given the paucity of randomized controlled study and high-quality data. However, the literature on the effective use of biologic therapies is rapidly expanding. This article reviews the epidemiology, clinical characteristics, histopathologic features, and management of pyoderma gangrenosum as well as Sweet’s syndrome, sub-corneal pustular dermatoses and bowel-associated dermatosis arthritis syndrome. The use of biologic agents, including tumor necrosis factor α-inhibitors, anti-IL1, anti-IL-17, and IL-23 are discussed in detail.
- 31 December 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (1) , 46-58
Novel Therapeutic Approaches and Targets for the Treatment of Neutrophilic Dermatoses, Management of Patients with Neutrophilic Dermatoses and Future Directions in the Era of Biologic Treatment
: Neutrophilic dermatoses are a heterogeneous group of inflammatory skin disorders characterized by the presence of a sterile, predominantly neutrophilic infiltrate on histopathology. Universally accepted and validated guidelines for the management of neutrophilic dermatoses do not exist, also given the paucity of randomized controlled study and high-quality data. However, the literature on the effective use of biologic therapies is rapidly expanding. This article reviews the epidemiology, clinical characteristics, histopathologic features, and management of pyoderma gangrenosum as well as Sweet’s syndrome, sub-corneal pustular dermatoses and bowel-associated dermatosis arthritis syndrome. The use of biologic agents, including tumor necrosis factor α-inhibitors, anti-IL1, anti-IL-17, and IL-23 are discussed in detail.
- Open Access
- 7 December 2020
- Published by MDPI AG in Antioxidants
- Vol. 9 (12) , 1238
Paraoxonase-2 Silencing Enhances Sensitivity of A375 Melanoma Cells to Treatment with Cisplatin
Melanoma represents the most aggressive skin cancer, being responsible for the majority of deaths related with these neoplasms. Despite chemotherapy represents a frontline approach for management of the advanced stages of the disease, it displayed poor response rates and short-term efficacy due to melanoma cell resistance. Therefore, the discovery of molecules that can be used for effective targeted therapy of melanoma is crucial. In this study, we evaluated the impact of paraoxonase-2 (PON2) silencing on proliferation, viability, and resistance to treatment of the A375 melanoma cell line with chemotherapeutic drugs dacarbazine (DTIC) and cisplatin (CDDP). Due to the enzymes ability to counteract oxidative stress, we also evaluated the effect of enzyme knockdown on reactive oxygen species (ROS) production in cells treated with CDDP. The data reported clearly demonstrated that PON2 knockdown led to a significant reduction of cell proliferation and viability, as well as to an enhancement of A375 sensitivity to CDDP treatment. Moreover, enzyme downregulation was associated with an increase of ROS production in CDDP-treated cells. Although further analyses will be necessary to understand how PON2 could influence melanoma cell metabolism and phenotype, our results seem to suggest that the enzyme may serve as an interesting molecular target for effective melanoma treatment.
- 7 December 2020
- Published by MDPI AG in Antioxidants
- Vol. 9 (12) , 1238
Open AccessParaoxonase-2 Silencing Enhances Sensitivity of A375 Melanoma Cells to Treatment with Cisplatin
Melanoma represents the most aggressive skin cancer, being responsible for the majority of deaths related with these neoplasms. Despite chemotherapy represents a frontline approach for management of the advanced stages of the disease, it displayed poor response rates and short-term efficacy due to melanoma cell resistance. Therefore, the discovery of molecules that can be used for effective targeted therapy of melanoma is crucial. In this study, we evaluated the impact of paraoxonase-2 (PON2) silencing on proliferation, viability, and resistance to treatment of the A375 melanoma cell line with chemotherapeutic drugs dacarbazine (DTIC) and cisplatin (CDDP). Due to the enzymes ability to counteract oxidative stress, we also evaluated the effect of enzyme knockdown on reactive oxygen species (ROS) production in cells treated with CDDP. The data reported clearly demonstrated that PON2 knockdown led to a significant reduction of cell proliferation and viability, as well as to an enhancement of A375 sensitivity to CDDP treatment. Moreover, enzyme downregulation was associated with an increase of ROS production in CDDP-treated cells. Although further analyses will be necessary to understand how PON2 could influence melanoma cell metabolism and phenotype, our results seem to suggest that the enzyme may serve as an interesting molecular target for effective melanoma treatment.
- 1 December 2020
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 155 (6) , 791-793
Familial lupus panniculitis: two cases, same diagnosis, what evolution?
- 1 December 2020
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 155 (6) , 791-793
Familial lupus panniculitis: two cases, same diagnosis, what evolution?